Mielodiszplasztikus szindróma (MDS): vizsgálatok itt: Németország
28 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 2026. november 15.. Ask the study team whether a trial fits you.
- 3. fázisTaking peoplePhase III Study of Induction and Consolidation Chemotherapy With Venetoclax in Patients With Newly Diagnosed AML or MDS-EB-2
- Where
- Arnsberg, Aschaffenburg, Bad Saarow, Berlin, Bochum, Bonn, Bremen, Brunswick, Darmstadt, Dortmund, Frankfurt Am Main, Giessen, Goch, Greifswald, Halle (Saale), Hamburg, Hamm, Hannover, Hanover, Heilbronn, Herne, Homburg, Kaiserslautern, Karlsruhe, Lübeck, Ludwigshafen Am Rhein, Magdeburg, Mainz, Minden, Munich, Offenburg, Oldenburg, Regensburg, Rostock, Stuttgart, Traunstein, Trier, Tuebingen, Ulm, Villingen-Schwenningen, Wuppertal
- Életkor
- 18 év to 75 év
- People
- 650 worldwide
- Run by
- University of Ulm
See details and how to joinNCT04628026 · EU 2023-507518-28-00 - 2. fázisTaking peopleVenetoclax- Augmented Treosulfan-Based Reduced Intensity Conditioning Before Allogeneic Stem Cell Transplantation
- Where
- Tuebingen
- Életkor
- 18 év to 75 év
- People
- 27
- Run by
- University Hospital Tuebingen
See details and how to joinNCT07214064 · EU 2025-521372-62-00 - 1. fázisNot yet taking people in NémetországA Phase 1 Study of JNJ-95804306 for Relapsed or Refractory Hematological Malignancies
- Where
- Berlin, Munich, Ulm
- People
- 225 worldwide
- Run by
- Janssen Cilag International
See details and how to join2026-525234-39-00 - 3. fázisTaking peopleA Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions
- Where
- Berlin, Bonn, Duesseldorf, Halle (Saale), Leipzig, Magdeburg
- Életkor
- 18 év and over
- People
- 225 worldwide
- Run by
- Takeda
See details and how to joinNCT06499285 · EU 2024-516009-22-00 - 3. fázisNot yet taking people in NémetországA Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Lower Risk Myelodysplastic Syndromes (LR-MDS) Who Need Regular Blood Transfusions
- Where
- Bayreuth, Berlin, Halle (Saale), Muenster
- Életkor
- 18 év and over
- People
- 300 worldwide
- Run by
- Takeda
See details and how to joinNCT07422480 · EU 2025-523544-12-00 - No phaseTaking peopleFirst-Line Luspatercept in Transfusion-Dependent Lower-Risk Myelodysplastic Neoplasms
- Where
- Mainz
- Életkor
- 18 év and over
- People
- 190
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT07752121 - 1/2. fázisTaking peopleStudy of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression
- Where
- Dresden, Frankfurt Am Main, Halle (Saale), Heidelberg, Munich, Ulm
- Életkor
- 16 év and over
- People
- 85 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07155226 · EU 2025-521299-76-00 - 2. fázisFut, nem toborozA Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS)
- Where
- Bayreuth, Berlin, Bonn, Duesseldorf, Esslingen am Neckar, Halle (Saale), Mainz
- Életkor
- 18 év and over
- People
- 210 worldwide
- Run by
- Takeda
See details and how to joinNCT04419649 · EU 2023-507469-24-00 - 1/2. fázisTaking peopleAZALOX Study: Safety and Efficacy of PXS-5505 with 5-Azacitidine in MDS and CMML Patients
- Where
- Bonn, Dresden, Duesseldorf, Goettingen, Hanover, Luebeck, Mainz, Mannheim, Munich, Oldenburg
- Életkor
- 18 év and over
- People
- 42
- Run by
- Heidelberg University
See details and how to join2024-517237-40-00 - 2. fázisFut, nem toborozA Study to Assess the Effectiveness and Safety of Pacritinib in Patients With VEXAS Syndrome (PAXIS)
- Where
- Dresden, Düsseldorf, Hamburg, Lübeck, Munich, Tübingen
- Életkor
- 18 év and over
- People
- 156 worldwide
- Run by
- Swedish Orphan Biovitrum
See details and how to joinNCT06782373 · EU 2024-516347-41-00 - 3. fázisTaking peopleLisaftoclax (APG-2575) Combined With Azacytidine (AZA) in the Treatment of Patients With Higher-risk Myelodysplastic Syndrome (GLORA-4).
- Where
- Berlin, Dresden, Duesseldorf, Halle (Saale), Leipzig, Stuttgart, Ulm
- Életkor
- 18 év and over
- People
- 490 worldwide
- Run by
- Ascentage Pharma Group Inc.
See details and how to joinNCT06641414 · EU 2024-517247-31-00 - 2/3. fázisTaking peopleA Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
- Where
- Brunswick, Freiburg im Breisgau, Halle Saale, Heidelberg
- Életkor
- 18 év and over
- People
- 316 worldwide
- Run by
- Taiho Oncology, Inc.
See details and how to joinNCT04256317 · EU 2024-515098-93-00 - 4. fázisTaking peopleRegistry and clinical trial comparing standard intensity and reduced intensity treatment in patients with AML or CLL who do not have residual disease.
- Where
- Augsburg, Berlin, Bochum, Brunswick, Chemnitz, Cologne, Dresden, Erfurt, Essen, Frankfurt Am Main, Greifswald, Halle (Saale), Hamburg, Hanover, Herne, Jena, Kiel, Leipzig, Magdeburg, Muenster, Munich, Regensburg, Rostock, Tuebingen, Ulm
- Életkor
- 18 év and over
- People
- 365 worldwide
- Run by
- Medizinische Hochschule Hannover
See details and how to join2024-512503-39-00 - 1/2. fázisTaking peopleVenetoclax in Addition to Sequential Conditioning With Fludarabine / Amsacrine / Ara-C (FLAMSA) + Treosulfan for Allogeneic Blood Stem Cell Transplantation in Patients With MDS, CMML or sAML
- Where
- Aachen, Cologne, Duesseldorf, Frankfurt Am Main, Jena, Munich
- Életkor
- 18 év and over
- People
- 38
- Run by
- Heinrich-Heine University, Duesseldorf
See details and how to joinNCT05807932 · EU 2024-514688-24-00 - 2. fázisFut, nem toboroz(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
- Where
- Aachen, Freiburg im Breisgau, Lübeck, Mannheim
- Életkor
- 18 év and over
- People
- 140 worldwide
- Run by
- Cogent Biosciences, Inc.
See details and how to joinNCT04996875 · EU 2024-511407-42-00 - 1/2. fázisTaking peopleA Study of BGB-11417 in Participants With Myeloid Malignancies
- Where
- Leipzig, Ulm
- Életkor
- 18 év and over
- People
- 260 worldwide
- Run by
- BeOne Medicines
See details and how to joinNCT04771130 · EU 2023-508881-14-00 - 3. fázisTaking peopleIvosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an IDH1 Mutation
- Where
- Dresden, Duesseldorf, Goettingen, Hanover, Leipzig, Munich
- Életkor
- 18 év and over
- People
- 48 worldwide
- Run by
- Institut de Recherches Internationales Servier
See details and how to joinNCT06465953 · EU 2023-510155-37-00 - 2. fázisTaking peopleEvaluation of Treosulfan Versus Melphalan Conditioning Followed by PTCy in Patients With AML and MDS Undergoing Allogeneic Transplantation
- Where
- Aachen, Augsburg, Berlin, Chemnitz, Cologne, Dresden, Frankfurt am Main, Greifswald, Halle, Jena, Kiel, Leipzig, Mainz, Münster, Nuremberg, Rostock, Stuttgart
- Életkor
- 18 év and over
- People
- 220
- Run by
- Technische Universität Dresden
See details and how to joinNCT07025824 - No phaseNot yet taking people in NémetországDresden MDS Registry With an Accompanying Biomaterial Collection
- Where
- Dresden
- Életkor
- 18 év and over
- People
- 500
- Run by
- Technische Universität Dresden
See details and how to joinNCT07561385 - 2. fázisTaking peopleProspective Evaluation of Ivosidenib Maintenance Following Allogeneic Stem Cell Transplantation in Patients With Acute Myeloid Leukemia or High-risk Myelodysplastic Neoplasia With IDH1 (Isocitrate Dehydrogenase 1) Mutation
- Where
- Aachen, Chemnitz, Dresden, Erlangen, Essen, Frankfurt Am Main, Greifswald, Halle (Saale), Hamburg, Jena, Kiel, Leipzig, Mainz, Mannheim, Muenster, Munich, Oldenburg, Rostock, Ulm
- Életkor
- 18 év to 75 év
- People
- 76
- Run by
- Technische Universität Dresden
See details and how to joinNCT06717958 · EU 2023-509055-14-00 - 2. fázisBefejeződöttA Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose)
- Where
- Brunswick, Luebeck
- Életkor
- 18 év and over
- People
- 332 worldwide
- Run by
- Taiho Oncology, Inc.
See details and how to joinNCT04093570 · EU 2024-516293-29-01 - 1/2. fázisNot yet taking people in NémetországA Study to Evaluate S241656 Alone or in Combination in Participants With Selected Myeloid Malignancies
- Where
- Berlin, Dresden, Heidelberg, Jena, Leipzig, Munich, Ulm
- Életkor
- 18 év and over
- People
- 64 worldwide
- Run by
- Servier
See details and how to joinNCT07719348 · EU 2025-525128-88-00 - 3. fázisBefejeződöttA Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials
- Where
- Berlin, Dresden, Düsseldorf, Halle, Hamburg, Hanover, Leipzig, Mainz, München
- Életkor
- 18 év and over
- People
- 665 worldwide
- Run by
- Celgene
See details and how to joinNCT04064060 - 2. fázisTaking peopleA Study of Momelotinib in Participants With Low-risk Myelodysplastic Syndrome
- Where
- Dresden, Leipzig, Luebeck, Mainz, Muenster, Munich
- Életkor
- 18 év and over
- People
- 80 worldwide
- Run by
- GlaxoSmithKline
See details and how to joinNCT06847867 · EU 2024-519928-24-00 - No phaseTaking peopleStudy for Epidemiology and Characterization of Myelodysplastic Syndromes (MDS) and Juvenile Myelomonocytic Leucemia (JMML) in Childhood
- Where
- Freiburg im Breisgau
- Életkor
- Up to 17 év
- People
- 260
- Run by
- University Hospital Freiburg
See details and how to joinNCT00662090